Lenalidomide Olainfarm

Lenalidomide, the active ingredient in Lenalidomide Olainfarm, is an immunomodulatory imide drug (IMiD) presented as an appropriate‑strength tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle‑cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery and support for clinical programs across multiple regions.

Lenalidomide is used in hematologic malignancies to control disease progression and improve survival.

Multiple myeloma: reduces tumor burden, delays disease progression, and prolongs progression‑free and overall survival in eligible adult patients. Myelodysplastic syndromes with del(5q): improves red blood cell production, corrects anemia, and reduces the need for blood transfusions in patients with this cytogenetic abnormality. Mantle cell lymphoma: induces tumor regression, achieves partial or complete remission, and extends overall survival in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels leading to bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Lenalidomide therapy, several precautions should be considered to ensure patient safety. - Pregnancy: contraindicated; effective contraception required for both patient and male partners. - Renal impairment: dose adjustment may be needed based on creatinine clearance. - Hematologic monitoring: regular blood counts to detect neutropenia or thrombocytopenia. - Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. - Drug interactions: review concomitant medications for CYP or immunomodulatory effects. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): may enhance immunosuppressive effects.

Moderate Interactions (Monitor Closely): - P-glycoprotein substrates (e.g., digoxin): possible altered levels. - Vaccines (live attenuated): reduced vaccine efficacy; avoid during therapy. - Other myelosuppressive agents (e.g., chemotherapy): additive bone marrow suppression.